2 citations
,
November 2021 in “Journal of Clinical Psychopharmacology” This article provides no new research results, focusing instead on International Consortium for Mood and Psychotic Disorder Research's topics and types of collaborations.
February 2006 in “Inpharma Weekly”
10 citations
,
May 2018 in “Neuropharmacology” This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.
January 2025 in “Journal of Prescribing Practice” 3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery” 1 citations
,
January 2007 in “Zhōnghuá yàoxué zázhì” In this study, ethosomes were more effective than liposomes for delivering finasteride through human skin, showing higher transdermal flux and accumulation, especially in deeper skin layers.
January 2016 in “SHILAP Revista de lepidopterología” This paper presents a case where alopecia was associated with the use of escitalopram and improved after switching to duloxetine, alongside a literature review of antidepressant-related alopecia.
February 2020 in “Definitions” 19 citations
,
April 2011 in “Headache The Journal of Head and Face Pain” This study found that both topiramate and divalproex sodium were similarly effective in reducing headache frequency by over 50% among episodic migraine patients after three months of treatment.
49 citations
,
September 2015 in “Psychoneuroendocrinology” This study suggests that the 5α-reductase inhibitor finasteride modulates sensorimotor gating in rats by affecting D1 and D3 receptors, but not D2 receptors, with varying effects based on genetic strain.
January 2023 in “RSC Advances” This study found that two eco-friendly analytical methods for quantifying Finasteride and Tadalafil in a new dosage form were effective, green, and suitable for quality control.
9 citations
,
April 2007 in “Journal of Andrology” This article reviews the management of excessive pre-ejaculate, highlighting case reports where 5-α-reductase inhibitors, such as finasteride and dutasteride, led to symptom resolution in patients reporting distress due to this condition.
August 2018 in “Journal of The American Academy of Dermatology”
April 1992 in “Current opinion in therapeutic patents” This study reports the development of novel 4-amido-Δ4,6-steroids as potential inhibitors of 5α-reductase, showing promising in vitro results for conditions like acne and benign prostatic cancer.
20 citations
,
September 2019 in “Epidemiology and Psychiatric Sciences” This review discusses post-SSRI sexual dysfunction syndrome and highlights its significant clinical and regulatory implications, but reports no new findings.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” This study found that activating liver X receptors with an agonist reduced skin fibrosis in experimental models, particularly in inflammation-driven conditions, by inhibiting macrophage infiltration and interleukin-6 release.
1 citations
,
December 1970 in “European journal of endocrinology” This study reports experience treating 140 women with hirsutism and other virilism signs using cyproterone acetate and ethinyl estradiol, focusing on those treated for over five months.
January 2012 in “The Journal of Clinical Psychiatry”
February 2025 in “International Urology and Nephrology” In this study, mild improvements in erectile function, penile sensitivity, and nocturnal erections were observed in male patients with post-drug syndrome following a 16-week treatment targeting the peripheral nerves of the genitalia, but significant symptoms persisted, indicating further research is essential.
9 citations
,
February 2018 in “Journal of Pharmaceutical and Biomedical Analysis” This study validated a highly selective and fast LC–MS/MS method for accurately measuring levels of tadalafil and finasteride in human plasma, adhering to international bioanalytical guidelines.
11 citations
,
January 2020 in “Epidemiology and Psychiatric Sciences” Antidepressants can cause long-term side effects like severe withdrawal symptoms and sexual dysfunction, which can last for months or years after stopping the medication.
April 2012 in “Reactions Weekly” Finasteride may cause more sexual side effects than previously thought.
2 citations
,
October 2021 in “Journal of Cosmetic Dermatology” In this randomized trial, the researchers observed that both montelukast and finasteride effectively reduced acne severity and lesion count in women with moderate acne, but finasteride showed greater efficacy. Both medications had transient, non-serious side effects, indicating satisfactory tolerability and safety.
February 2006 in “PubMed” In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.
55 citations
,
December 2006 in “Journal of The American Academy of Dermatology” This review discusses the potential for SSRIs to cause serious skin reactions and suggests considering alternative antidepressants if such reactions occur.
24 citations
,
December 2013 in “Sexual medicine reviews” This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.
July 2006 in “Inpharma Weekly”
24 citations
,
May 2015 in “Schizophrenia Research” This study found that inhibiting the enzyme 5α-reductase with finasteride counteracted stress-induced prepulse inhibition deficits in socially isolated rats by altering neuroactive steroid concentrations in the brain.
60 citations
,
December 2013 in “PLoS ONE” The researchers found that inhibiting soluble epoxide hydrolase, either genetically or pharmacologically, delayed the onset of chemically induced seizures related to GABA antagonism in experimental models.
April 2023 in “Tikrit Journal of Pharmaceutical Sciences” In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.